DelMar Pharma Invited to Present at Leading Life Sciences Conference
February 18, 2011 - Vancouver, British Columbia - Del Mar Pharmaceuticals is proud to announce that it has been invited to present at the 11th Annual Life Science Innovation Northwest Conference – the Pacific Northwest’s premier life sciences conference, on March 2-3, 2011 at the Washington State Convention Center in Seattle, Washington.
The conference is sponsored by The Washington Biotechnology & Biomedical Association (WBBA), in partnership with Burrill & Company.
Mr Jeffrey Bacha, Del Mar Pharmaceuticals’ President & CEO will present an overview of the company’s drug development programs to an audience of industry leaders and life science investors.
About Del Mar Pharma
Del Mar Pharmaceuticals is focused on the development and commercialization of proven cancer therapies in high-impact orphan drug indications. The Company’s lead product, VAL-083, VAL-083 benefits from an extensive clinical and pre-clinical research history via studies sponsored by the National Cancer Institute in the United States. Previously published clinical data demonstrate efficacy of chemotherapy with VAL-083 in the treatment GBM and other tumor types.
Released February 18, 2011